Eli Lilly (LLY): Cash Flow Discount Meets Earnings Premium
Eli Lilly (LLY) trades at ~$1,213 after a 441.5% five-year return. While DCF analysis points to potential upside, traditional valuation metrics show a premium. The GLP-1 obesity and diabetes franchise remains the key growth driver.
Key Numbers
According to an analysis by Simply Wall St., Eli Lilly (LLY) stock is currently trading around $1,213 per share, having delivered a cumulative return of 441.5% over five years. This strong long-term performance raises the bar for what constitutes an attractive entry point.
DCF vs. Market Metrics
A Discounted Cash Flow (DCF) model suggests the stock may be undervalued, implying potential upside. However, other valuation metrics such as the price-to-earnings (P/E) ratio indicate the stock trades at a premium compared to sector averages. This divergence between cash flow discount and earnings premium creates a mixed valuation picture.
Key Growth Driver: GLP-1
The biggest bet on Eli Lilly's future lies in its GLP-1 drug franchise for obesity and diabetes, which is experiencing surging demand. Expectations for this category could become a major revenue source in coming years, supporting long-term growth.
What This Means for Investors
Eli Lilly offers an investment opportunity tied to the future growth of GLP-1 drugs, but the current price already reflects much of that optimism. Investors must weigh the potential upside from DCF against the risk of paying a premium based on earnings multiples.
Frequently Asked Questions
Found this useful? Share it